When a scan shows pancreatic cancer has already spread, the options are limited and time feels short. A small early trial at Cedars-Sinai suggests that adding a simple amino acid called L-glutamine to standard chemotherapy may help some patients. The researchers stress that it’s far too early to call it a breakthrough.
Key Takeaways
- In a 16-patient trial, tumors shrank in 15 people (94%) who took high-dose oral L-glutamine alongside standard chemotherapy for advanced pancreatic cancer. The study was published in Nature Cancer on August 31, 2026.
- Two patients’ tumors disappeared on scans, and median survival reached 22 months. Standard chemotherapy alone has historically produced roughly 8 to 13 months.
- The trial had no comparison group, so it can’t show that glutamine caused the better results. The authors say their findings don’t prove the combination beats chemo alone.
- Researchers think glutamine may make cancer cells more sensitive to chemotherapy and support gut health in patients who struggle to absorb nutrients.
- Patients should not start glutamine on their own. The trial used a high, medically supervised dose, and larger randomized studies are still needed.
What the trial found
The phase 1 trial, called GlutaPanc, enrolled people with advanced pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer, who had not yet started treatment. Fifteen had cancer that had spread to other organs. All received the standard first-line chemotherapy combination of gemcitabine and nab-paclitaxel, plus oral L-glutamine twice daily at doses of up to 30 grams a day.
Results among the 16 evaluable patients:
- 2 (12.5%) had a complete response, meaning their tumors were no longer visible on imaging.
- 5 (31%) had a partial response, meaning their tumors shrank substantially.
- 8 (50%) had stable disease.
- 1 saw the cancer grow.
Median progression-free survival, how long patients lived before the cancer worsened, was 8.5 months. Median overall survival was 22 months, and about 40% of patients were still alive at two years.
That compares favorably with past results. In the major trial that established gemcitabine plus nab-paclitaxel as a standard treatment, median survival was about 8.5 months. But comparing one small trial with an older, much larger one is risky, because the patients and their care may differ in important ways.
Why glutamine?
Glutamine is the most abundant amino acid in the blood. It’s also a fuel many cancer cells use, so adding more of it may sound counterintuitive.
The Cedars-Sinai team originally hoped glutamine would protect patients’ guts. People with pancreatic cancer often absorb nutrients poorly and can develop cachexia, a dangerous wasting of weight and muscle. Glutamine is known to help the intestinal lining heal, and about half of the trial’s patients maintained their weight.
In laboratory work, the researchers also found that cancer cells exposed to high doses of glutamine became especially vulnerable to chemotherapy. That fits the tumor shrinkage seen in patients. They also found that how patients’ gut bacteria responded to glutamine was linked to how well they did. That finding is early and needs more study.
What the trial can’t tell us
This was a small, single-hospital safety and dose-finding study, not a test of whether the treatment works better than chemo alone. Every patient received glutamine, so there’s no way to know how they would have done without it. In the published paper, the authors state that their results do not support the claim that the combination is better than chemotherapy alone, and they call for a randomized trial.
Side effects were common, as is typical with this chemotherapy. About two-thirds of patients had serious (grade 3 or higher) treatment-related side effects, which the researchers attributed mainly to the chemotherapy rather than the glutamine. Several of the researchers have a pending patent related to the work.
An important safety note: The trial used pharmaceutical-grade L-glutamine, a product the FDA has approved for sickle cell disease, at carefully controlled doses under close medical supervision. Supplements sold in stores aren’t held to the same standards. Because some cancers use glutamine for growth, its effects may depend on the type of cancer and the treatment. Anyone with cancer should talk to their oncology team before taking glutamine or any other supplement during treatment.
What’s next
The investigators say the results justify a larger randomized trial, in which some patients receive glutamine with chemotherapy and others receive chemotherapy alone. Only that kind of study can show whether glutamine truly improves survival.
Pancreatic cancer remains one of the deadliest cancers, partly because it’s usually found late. If you have a family history of pancreatic cancer, or symptoms such as unexplained weight loss, new-onset diabetes, yellowing skin or persistent upper abdominal or back pain, talk to your doctor.
This isn’t a substitute for medical advice. Talk to your doctor about what’s right for you.
Sources:
- Gong J, Bhowmick NA, et al. L-Glutamine in combination with first-line gemcitabine and nab-paclitaxel in advanced pancreatic ductal adenocarcinoma: an open-label, single-arm, phase 1 GlutaPanc trial. Nature Cancer, 2026.
- Cedars-Sinai. Study: Supplement plus chemo boosts pancreatic cancer survival. August 31, 2026.